Center of Organ Fibrosis and Remodeling, Jiangsu Key Lab of Molecular Medicine, Nanjing University School of Medicine, Nanjing, China.
Laboratory of Pathology, Key Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Cell Death Differ. 2021 Mar;28(3):1001-1012. doi: 10.1038/s41418-020-00631-9. Epub 2020 Oct 6.
Development of renal fibrosis is a hallmark of renal aging and chronic kidney disease of all etiologies and characterized by extensive renal cell injuries and subsequent myofibroblast transdifferentiations (MTDs), which are significantly influenced by aberrant histone deacetylase (HDAC) activities. However, the key HDAC isoforms and effectors that are causally involved in the processes remain poorly understood. Here, we report that aberrant HDAC3 induction and its inhibition of Klotho, a renal epithelium-enriched aging suppressor, contribute significantly to renal fibrogenesis. HDAC3 was preferentially elevated with concomitant Klotho suppression in fibrotic kidneys incurred by unilateral ureter obstruction (UUO) and aristolochic acid nephropathy (AAN), whereas Hdac3 knockout resisted the fibrotic pathologies. The HDAC3 elevation is substantially blocked by the inhibitors of TGFβ receptor and Smad3 phosphorylation, suggesting that TGFβ/Smad signal activates Hdac3 transcription. Consistently, an HDAC3-selective inhibitor RGFP966 derepressed Klotho and mitigated the renal fibrotic injuries in both UUO and AAN mice. Further, HDAC3 overexpression or inhibition in renal epithelia inversely affected Klotho abundances and HDAC3 was inducibly associated with transcription regulators NCoR and NF-kB and bound to Klotho promoter in fibrotic kidney, supporting that aberrant HDAC3 targets and transcriptionally inhibits Klotho under renal fibrotic conditions. More importantly, the antirenal fibrosis effects of RGFP966 were largely compromised in mice with siRNA-mediated Klotho knockdown. Hence, HDAC3 aberration and the subsequent Klotho suppression constitute an important regulatory loop that promotes MTD and renal fibrosis and uses of HDAC3-selective inhibitors are potentially effective in treating renal fibrotic disorders.
肾纤维化的发展是肾脏老化和各种病因引起的慢性肾脏病的标志,其特征是广泛的肾细胞损伤和随后的肌成纤维细胞转分化(MTD),这一过程受到异常组蛋白去乙酰化酶(HDAC)活性的显著影响。然而,导致这一过程的关键 HDAC 同工型和效应物仍知之甚少。在这里,我们报告异常的 HDAC3 诱导及其对肾脏上皮细胞中富含的衰老抑制因子 Klotho 的抑制作用,对肾纤维化的发生有重要贡献。在单侧输尿管梗阻(UUO)和马兜铃酸肾病(AAN)引起的纤维化肾脏中,HDAC3 优先升高,同时伴随着 Klotho 的抑制,而 Hdac3 基因敲除则抵抗了纤维化病变。HDAC3 的升高被 TGFβ 受体和 Smad3 磷酸化抑制剂显著阻断,表明 TGFβ/Smad 信号激活了 Hdac3 的转录。一致地,HDAC3 选择性抑制剂 RGFP966 重新表达 Klotho,并减轻了 UUO 和 AAN 小鼠的肾脏纤维化损伤。此外,HDAC3 在肾脏上皮细胞中的过表达或抑制会反向影响 Klotho 的丰度,HDAC3 可与转录调节剂 NCoR 和 NF-kB 诱导性结合,并与纤维化肾脏中的 Klotho 启动子结合,这表明在肾脏纤维化条件下,异常的 HDAC3 靶向并转录抑制 Klotho。更重要的是,在 siRNA 介导的 Klotho 敲低小鼠中,RGFP966 的抗肾纤维化作用在很大程度上受到了影响。因此,HDAC3 的异常和随后的 Klotho 抑制构成了一个重要的调节环,促进了 MTD 和肾脏纤维化,而使用 HDAC3 选择性抑制剂在治疗肾脏纤维化疾病方面具有潜在的疗效。